Szarkóma: vizsgálatok itt: Grúzia

1 trial · From ClinicalTrials.gov, checked 2026. november 12.. Ask the study team whether a trial fits you.

• 3. fázisTaking people
  A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

  Where

  Batumi, Kutaisi, Tbilisi

  Életkor

  18 év and over

  People

  348 worldwide

  Run by

  Merck Sharp & Dohme LLC

  See details and how to joinNCT06345729 · EU 2023-507776-42-00